This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

C. J. WATSON, M.D.; W. W. SPINK, M.D.

Arch Intern Med. 1940;65(4):825-846.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Since sulfanilamide has come into general use, a number of reports have appeared indicating that jaundice¹ and hemolytic anemia² are toxic effects that may be encountered. One gains the impression from the majority of these reports that such complications are rarely encountered and that they are probably due to drug idiosyncrasy. Long and his associates^1g observed but 2 patients with jaundice (without hemolytic anemia) among 408 treated with sulfanilamide. In the material from the same clinic, Wood^2b noted that acute anemia developed in 21 of 522 persons to whom the drug was administered. He found the incidence of anemia to be 8.3 per cent in children as compared with 2.4 per cent in adults. He ascribed the anemia in the 21 cases to hemolysis, because of the abrupt appearance of jaundice and urobilinuria. In 8 additional instances a "slow" type of anemia was encountered, which was similar to that previously . . . [Full Text PDF of this Article]

Author Affiliations
With the Technical Assistance of Ruth L. Evarts MINNEAPOLIS

From the Division of Internal Medicine, University of Minnesota Hospital.

Footnotes
Aided by a grant from the research fund of the Graduate School, University of Minnesota.

Assistance in the preparation of materials was furnished by the personnel of Works Progress Administration Official Project No. 665-71-3-69.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?